

Corporate Presentation January 2024

SRC

DO NOT DISTRIBUTE WITHOUT PERMISSION | 2024

DISCLAIMER

This presentation has been prepared by Compass Therapeutics, Inc. ("we," "us," "our," or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation includes forward-looking statements regarding our drug candidates, the timing and outcome of regulatory decisions, future availability of clinical trial data, our collaborations for our product candidates and the maintenance of those collaborations, business and results from operations, and other matters. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including without limitation: that our drug candidates do not advance in development or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of clinical trials; that many drug candidates that have completed early-stage trials do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; regulatory developments; our ability to protect our intellectual property rights, and unexpected costs, charges or expenses that reduce cash runway. Our pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. These and other risks and uncertainties that we face are described in our most recent Annual Report on Form 10-K, and in other filings that we make with the Securities and Exchange Commission from time to time. We undertake no obligation to update forward-looking statements as a result of new information or otherwise.


This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation concerns drugs that are under clinical investigation, and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). It is currently limited by Federal law to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.



Corporate Highlights

We are a clinical stage biotech company developing antibody therapeutics for cancer



Focused Pipeline with Multiple Value Inflection Points

Program	Target	Discovery	IND Enabling Pre-Clinical	Phase 1	Phase 2	Phase 3	Next Milestone
		COMPANION-002	2: BTC				Top line data in U.S. H2 2024
CTX-009 DLL4 x VEGF-A	COMPANION-003	3: Colorectal				Top line data in U.S. Mid-2024	
		COMPANION-004	: TBD				Initiate in U.S. H2 2024
CTX-471	CD137	CD137 agonist (m	nonotherapy)				Fully enrolled
	CD137 + PD-1 (c	mbination)*				Top line data in U.S. H1 2025	
CTX-8371	PD-1 x PD-L1	Solid Tumors					Initiate Phase 1 Q1 2024

*Clinical collaboration with Merck & Co. Inc., Rahway NJ USA in combination with anti-PD-1 therapy KEYTRUDA®



Leadership Team Experienced in Drug Discovery and Development



Jon Anderman VP, Head of Legal



Vered Bisker-Leib, PhD, MBA CEO



lan Chia, PhD VP, Business Development



Bing Gong, PhD VP, Protein Sciences



Karin Herrera VP, Clinical Operations



James Kranz, PhD VP, CMC



Neil Lerner, CPA, MIM VP, Finance



Minori Rosales, MD, PhD SVP, Head of Clinical Development



Kris Sachsenmeier, PhD VP, Translational Science



Thomas J. Schuetz, MD, PhD President of R&D and Vice Chairman




CTX-009 DLL4 X VEGF-A bispecific antibody




Overview of CTX-009

- Bispecific antibody blocking DLL4 (Notch-1 ligand) and VEGF-A (soluble ligand)
- Does not lead to ADCC, Fc inactive
- Binds to its targets with 2:2 valency
- At 10 mg/Kg, CTX-009 has approximately the same VEGF-A capturing ability as bevacizumab (Avastin)
- The only DLL4 X VEGF bispecific that demonstrated monotherapy activity in the clinic in colorectal and gastric cancer
- Durable responses in patients with cholangiocarcinoma seen in Phase 1b study of CTX-009 in combination with paclitaxel



Dual blockade of DLL4 and VEGF overcomes VEGF resistance





CTX-009 – Vision and Potential

Best-in-class DLL4 x VEGF-A bispecific

- Phase 3 ongoing in BTC
- Phase 2 ongoing in CRC

Oncology

Has demonstrated compelling activity in the 3rd line and 4th line settings in patients with Cholangiocarcinoma, Colorectal Cancer, Gastric Cancer and Pancreatic Cancer

Could become front line therapy in multiple solid tumors

Other potential indications based on DLL4 expression such as Ovarian Cancer & Renal Cell


Ophthalmology

Potential to address AMD and DME based on mechanism

Consideration for partnership




Phase 1a CTX-009 Monotherapy (all doses)





Phase 1b CTX-009 Combination Study





Phase 1 CTX-009 Safety Data

Phase 1a Monotherapy (n=45)

Drug-related adverse events observed in > 5% of patients	Total (n)	Total (%)	Grade 3 (n)	Grade 3 (%)
Hypertension*	17	38	7	16
General disorders (fatigue, fever, asthenia, edema, etc.)	7	16	1	2
Nervous system disorders (headache, dizziness)	7	16	1	2
Gastrointestinal disorders (nausea, vomiting, etc.)	6	13	2	4
Pulmonary hypertension	4	9	0	0
Proteinuria	3	7	0	0

Phase 1b Combination (n=17)

Drug-related adverse events observed in > 1 patient	Total (n)	Total (%)	Grade 3 (n)	Grade 3 (%)
Hypertension	8	47	4	24
Nausea	8	47	1	6
Fatigue	6	35	1	6
Neutropenia** Anemia** Thrombocytopenia**	6 4 2	35 24 12	2 3 2	12 18 12
Diarrhea	5	29	0	0
Anorexia	5	29	0	0
Proteinuria	5	29	0	0
Pulmonary hypertension (all grade 1)	5	29	0	0
Dyspnea	4	24	0	0
Gingival edema (mucositis)	2	12	0	0
Anal hemorrhage	2	12	0	0

* In clinical trials of bevacizumab, incidence of Grade 3-4 hypertension ranged between 5%-18% (Avastin label). It is typically managed by anti-hypertensive drugs




CTX-009 – Phase 1 Clinical Studies Summary

Overall Response Rate at the		Clinical Benefit Rate at the		
Efficacious Dose		Efficacious Dose		
(10-12.5 mg/kg)		(10-12.5 mg/kg)		
Monotherapy	Combination	Monotherapy	Combination	
18.8% ORR (3/16)	23.5% ORR (4/17)	68.8% (11/16)	76.5% (13/17)	



Phase 2 CTX-009 Combination Study (S. Korea)

Patients with biliary tract cancers after one or two prior therapies





Phase 2 CTX-009 Data

Patient Number **CONFIRMED PARTIAL RESPONSE** 12 13 7 8 9 10 11 14 15 18 19 20 21 5 6 16 17 0 -1 -10 -12 -12 -12 -17 -17 -20 -19 -20 -25 -30 -33 -33 Intrahepatic cholangiocarcinoma -37 -40 -38 Extrahepatic cholangiocarcinoma -41 -44 -44 Gallbladder cancer -48 -50 Ampullary cancer -52


Responses achieved across multiple BTC subclasses. Data as of November 9, 2022

2 patients were not evaluable (one missing post baseline scan; one had a scan outside of protocol window)

-60


Percent tumor decline

-57



22

CTX-009 Swimmer Plot





CTX-009 Phase 2 Results (Median follow-up of 12.1 months)

- 24 patients enrolled and dosed
- 1 patient remains on study


Endpoint	Value (95% CI)
Overall Response Rate (ORR)	37.5%
Stable Disease (SD)	54.2%
Progression Free Survival (PFS)	9.4 m (5.4 – 11.1)
Overall Survival (OS)	12.5 m (10.9 – NA)
Duration of Response	6.9 m (3.5 – NA)

Number of previous systemic therapies	ORR
Pts treated in the 2L [n=11]	7/11 (63.6%)
Pts treated in the 3L [n=13]	2/13 (15.4%)




Secondary Endpoints: PFS and OS

• Median PFS: 9.40 m (5.4-11.1)



• Median OS: 12.5 m (10.9-NA)





Treatment-Emergent ≥ Grade 3 Adverse Events (>10% of patients)

Phase 2 BTC study of CTX-009 plus paclitaxel

Event	24 total Patients N (%)
Neutropenia	20 (83.3%)
Anemia	5 (20.8%)
Hypertension	4 (16.7%)
Thrombocytopenia	3 (12.5%)

TEAE leading to discontinuation: confusion, embolism, pneumonia (grade 5), biliary fistula, large intestine perforation, blood creatinine increased, and blood urea nitrogen increased

Bevacizumab and paclitaxel label information

Event	Bevacizumab (label)	Paclitaxel (label)
Neutropenia		52%
Hypertension	5-18%	
Anemia		16%
Thrombocytopenia		7%
	Additional events: GI perforation, wound healing complications, Proteinuria, hemorrhage	Additional events: Hypersensitivity reactions, infections, bleeding, neuropathy



How Does CTX-009 Data Compared to Other BTC Studies?

Parameter	CTX-009 Mixed 2L and 3L N=24	FOLFOX (ABC-06) ¹ Only 2L N=81	Gem/Cis ² 1L N=204	Gem/Cis + Durv ³ Only 1L N=341
ORR	37.5% [64% 2L; 15% 3L]	5%	26%	26.7%
	,, ,			
OS	12.5 m	6.2 m	11.7 m	12.9 m
PFS	9.4 m	4.0 m	8.0 m	7.2 m
Any AE	100%	99%	55%	99.4%
Gr 3/4 AEs	92%	60%	71%	74%
Deaths (as Gr 5)	1 (4%)	10 (12%)	17 (8%)	13 (4%)
AEs leading to discontinuation	25%	~ 12%	10%	13%



1. Lamarca D, Lancet Oncol 2021; March 30

2. Valle, J. et al., N ENGL J MED, 362; 14 Apr 8, 2010, p. 1273

3. Oh, D. et al., *ESMO Poster 56P 2022*

DO NOT DISTRIBUTE WITHOUT PERMISSION | 2024

CTX-009 Phase 2 Study Summary

24 patients with BTC have been enrolled and dosed

9 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings (**64% ORR** of patients treated in the 2nd line setting)

Median PFS 9.4 months

Median OS 12.5 months

Adverse event profile similar to Phase 1 studies

Other regimens in BTC

FOLFOX (NCCN guidelines):5% ORR in the second-line setting4.0 month median PFS6.2 month median OS


TOPAZ-1 (Phase 3 study):

26.7% ORR for Gem/Cis/Durvalumab (anti PD-L1) in the first-line setting



COMPANION-002: Phase 2/3 U.S. BTC Study

Patients who have received one prior line of therapy



CTX-009: *BTC* Patient Demographics and Current Treatments

	US	EU5	Japan	Worldwide
Incident Cases	18,400 ¹	21,800 ²	14,329 ²	>200,000 ³


1L Treatment 2L Treatment					
Doublet chemo of gemcitabine + cisplatin (ABC-02 study) Or	FOLFOX 5% ORR 0.9 Mos OS Δ	FGFR2 mutation Pemigatinib (10-15% of CCA)	IDH1 mutation Ivosidenib (1-3% of BTC)	MSI-H tumors PD-1 Inhibitor (<1% of BTC)	Clinical trial
Gemcitabine/cisplatin + durvalumab (recently approved for 1L)					



1. NCI Surveillance, Epidemiology, and End Results (SEER) program

Delveinsight/company estimates
International Agency for Research on Cancer/GLOBOCAN

COMPANION-003: Phase 2 U.S. Colorectal Cancer (CRC) Study





CTX-009: CRC Patient Demographics and Current Treatments

	US	EU5	Japan	Worldwide
Incident Cases	153,020 ¹	246,734 ²	148,505 ²	1,931,590 ²
~50% Metastatic ³ 50-70% reach 3L ⁴	38,000-53,000 patients			

1L Treatment			2L Treatment		3L Treatment	
Chemotherapy FOLFOX/FOLFIRI	Bevacizumab or EGFR inhibitor + chemotherapy	Anti-PD-1 with MSI-H/dMMR mutation	Bevacizumab or EGFR + chemo	BRAF/EGFR with V600E mutation	Regorafenib	Trifluridine/ tipiracil
	chemotherapy			5-8% of CRC	ORR 1%, Median PFS 2.0 months	ORR 1-2%
		~5% of CRC				Median PFS ~2 months



- 1. NCI Surveillance, Epidemiology, and End Results (SEER) program
- 2. International Agency for Research on Cancer/GLOBOCAN
- 3. L Biller, D Schrag, JAMA 2021 Feb 16

4. Bekaii-Saab, Clin advances in Hem and Onc, Supp Jan 2021

DO NOT DISTRIBUTE WITHOUT PERMISSION | 2024

The COMPANION (COMPASS ANTI-ANGIOGENESIS) Studies

Top-line H2 2024

COMPANION 002 Phase 2/3 Randomized BTC study in the US **Top-line H1 2024**

COMPANION 003 Phase 2 study in third- and fourthline CRC in the US Initiate H2 2024

COMPANION 004 Phase 2 study in 3RD Solid Tumor Indication in the US

Evaluating additional indications for CTX-009 both as a monotherapy and in combination with chemotherapy



CTX-471 CD137 monoclonal antibody

CTX-471: Potential Best-in-Class CD137 Agonist

CTX-471: next generation CD137 agonist

Fully human, IgG4, optimized affinity for agonistic antibody

Unique epitope: non-ligand blocking

Phase 1 Study Update


Monotherapy in post checkpoint inhibitor patients

Monotherapy Phase 1a multiple ascending dose study completed

• MTD defined by immune thrombocytopenia

Monotherapy Phase 1b dose expansion study completed

- 1 CR: small cell lung cancer
- 4 PRs observed: melanoma (3 of 11) and mesothelioma (1 of 4)




JCI Insight. 2020;5(5):e133647



CTX-471: Complete Response in a Patient with Small Cell Lung Cancer

After progression on atezolizumab/chemo and nivolumab

- >> 66 y.o. man with advanced SCLC: Carboplatin/etoposide plus atezolizumab first line; nivolumab second line
- Confirmed, complete response (CR) by PET ~ 3 years on therapy





CTX-471 Clinical Development Plans

Phase 1b Monotherapy Study

Generally well tolerated

A complete response and four partial responses in the post PD-1/PD-L1 patient population

Small cell lung cancer, mesothelioma, and melanoma (three patients)

Phase 1b of CTX-471 with KEYTRUDA[®] in collaboration with Merck

Abbreviated CTX-471 dose escalation into the PD-1 regimen, followed by a cohort expansion

Post PD-1/PD-L1 Salvage Study


Dose escalation complete, no DLT

Dose expansion is ongoing



CTX-8371 PD-1 x PD-L1 bispecific antibody


StitchMabs[™] Platform was Utilized to Identify CTX-8371





CTX-8371: Differentiated MoA Leads to Enhanced T-Cell Activation


Converting PD-1 positive T cells into PD-1 negative T cells







CTX-8371 Pre-Clinical Proof of Concept

Activity in MC38-hPD-L1 model implanted in hPD-1/hPD-L1 transgenic mice







Group	% Cured	Tumor free / total
CTX-8371	62.5	5/8
Atezolizumab	12.5	1/8
IgG1 IC	0	0/8
Keytruda	25	2/8



Days post treatment

CTX-8371: Development Status

IND was accepted Currently opening clinical sites First patient dosing expected in 1Q 2024

Phase 1 study design

Multiple ascending dose, dose-escalation study

5 doses planned: 0.1, 0.3, 1.0, 3.0, and 10 mg/kg

Post PD-1 or PD-L1 patient population: Melanoma, NSCLC, HNSCC, Hodgkin's Lymphoma, TNBC

First patient dosing targeted for Q1 2024

Potential for proprietary combination regimens with CTX-009 and CTX-471



Compass Therapeutics Summary

Program Summary

>>>>

CTX-009 Novel DLL4 x VEGF-A bispecific antibody with both combination and monotherapy activity

Phase 1: Dose response established – responses in multiple indications

BTC Phase 2 results: 24 patients: 37.5% ORR (2L/3L), 63.6% (2L), median PFS 9.4 months, OS 12.5 months

COMPANION-002: BTC Phase 3 randomized study ongoing; top-line data expected H2 2024

COMPANION-003: CRC Phase 2 monotherapy study ongoing; top-line data expected mid-2024

CTX-471 Potential best-in-class CD137 agonist antibody with monotherapy activity

Phase 1 monotherapy study complete:

1 complete response (CR): small cell lung cancer (1 of 3), and 4 partial responses (PRs) in post PD-1 population: metastatic melanoma (3 of 11) and mesothelioma (1 of 4)

CTX-471 in combination with KEYTRUDA® dose escalation complete, dose expansion ongoing

CTX-8371 Next generation PD-1 x PD-L1 bispecific antibody

Unique MOA – enhances T-cell activation

IND cleared, currently opening clinical sites



Key 12 Month Milestones

